Mod GRF (1-29) & GHRP-6 Blend (10mg)
Mod GRF (1-29) & GHRP-6 Blend (10mg) is a pre-weighed blend of Mod GRF (1-29) 5mg and GHRP-6 5mg for laboratory research, HPLC-MS verified above 99% purity.
This product is currently out of stock. Email us to check the next available batch.
View wholesale pricing →Mod GRF (1-29) & GHRP-6 Blend (10mg): The Classic GHRH/GHRP Synergistic Combination — Pairing a Stabilized GHRH Analog with the Original Growth Hormone-Releasing Hexapeptide for Enhanced, Pulsatile Growth Hormone Secretion in Research Applications
The Mod GRF (1-29) & GHRP-6 Blend is a co-lyophilized 1:1 ratio formulation that pairs Mod GRF (1-29) (CJC-1295 without DAC) — a metabolically stabilized analog of growth hormone-releasing hormone (GHRH) with an approximately 30-minute half-life — with GHRP-6 (Growth Hormone-Releasing Hexapeptide), the original and most extensively studied member of the growth hormone-releasing peptide family[1]. GHRP-6, with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, was the first synthetic peptide shown to potently stimulate growth hormone release through the ghrelin receptor (GHS-R1a), and it remains the reference compound against which all newer GHRPs are compared[2]. This blend represents the prototypical "GHRH + GHRP" stack that has been widely investigated in both animal and human research for its ability to produce synergistic, amplified GH pulses exceeding the effects of either component administered alone[3].
Component Comparison: Mod GRF (1-29) vs. GHRP-6 vs. the Blend
| Property | Mod GRF (1-29) | GHRP-6 | Blend (1:1) |
|---|---|---|---|
| Receptor Target | GHRH Receptor (GHRHR) | Ghrelin Receptor (GHS-R1a) | Both receptors simultaneously |
| Peptide Type | GHRH analog (29 amino acids) | Synthetic hexapeptide (6 aa) | Combination formulation |
| Half-life | ~30 minutes (stabilized) | ~15-30 minutes | Short, pulsatile action |
| Intracellular Pathway | cAMP / PKA | PLC / IP3 / PKC | Dual pathway convergence |
| GH Peak (alone) | Moderate | Moderate-high | Synergistic (2-3x higher)[3] |
| Appetite Effect | Minimal | Significant orexigenic effect[4] | Moderate (GHRP-6 driven) |
| Prolactin/ACTH Effect | Minimal | Mild elevation at high doses | Minimal at standard doses |
| Key Substitutions | D-Ala2, Ala8, Gln29 (vs. native GHRH) | D-Trp2, D-Phe5 (non-natural amino acids) | — |
The scientific foundation for the GHRH + GHRP-6 combination rests on the well-documented synergistic interaction between these two receptor pathways. Growth hormone secretion from pituitary somatotrophs is under dual control: GHRH (released from the hypothalamic arcuate nucleus) stimulates GH synthesis and release via the GHRHR, while somatostatin (from the periventricular nucleus) tonically inhibits it[5]. GHRP-6 and related compounds act through the GHS-R1a receptor — originally identified as the target of synthetic GHRPs, later found to be the endogenous receptor for the stomach-derived hormone ghrelin[6]. GHS-R1a activation not only directly stimulates somatotroph GH release but also inhibits hypothalamic somatostatin secretion, thereby removing the "brake" on GH output and amplifying the response to GHRH[7].
Advantages of the Mod GRF + GHRP-6 Combination
- Well-documented synergy: The GHRH + GHRP-6 combination is the most extensively studied GHRH/GHRP pair in the literature, with multiple human clinical trials confirming synergistic GH release exceeding additive effects[3].
- Pulsatile physiological pattern: Both components are short-acting (half-lives measured in minutes), producing a transient GH peak that mimics the natural pulsatile secretion pattern — important for research examining the differential effects of pulsatile vs. continuous GH exposure on metabolism, body composition, and tissue growth[8].
- Metabolically stabilized GHRH component: Mod GRF (1-29) incorporates D-Ala2 and Ala8 substitutions that confer resistance to DPP-IV and endopeptidase degradation, making it significantly more stable and longer-acting than unmodified GHRH (1-29) while retaining the short-acting profile preferred for pulsatile protocols[9].
- Co-lyophilized convenience: Both peptides are lyophilized together in a single vial at a precise 1:1 weight ratio, eliminating the need for separate reconstitution and ensuring consistent, reproducible dosing in every injection.
- Extensive research history: GHRP-6 has been investigated in hundreds of preclinical and clinical studies since its discovery in the 1980s, making its pharmacology, safety profile, and GH-releasing efficacy among the best characterized of all synthetic peptide secretagogues[10].
References
- Bowers CY. Growth hormone-releasing peptide (GHRP) cell and animal studies. Journal of Pediatrics. 1996;128(2 Pt 2):S29-S35. (GHRP-6 discovery and development)
- Smith RG, et al. A new class of small molecules that release growth hormone in vitro and in vivo. Science. 1993;260(5113):1640-1643. (GHRP receptor characterization)
- Ishikawa S, et al. Synergistic effects of growth hormone-releasing peptide-6 and growth hormone-releasing hormone on growth hormone secretion in normal men. Journal of Clinical Endocrinology & Metabolism. 1998;83(5):1581-1585. (Human synergy study)
- Wren AM, et al. The hypothalamic mechanisms of appetite stimulation by growth hormone secretagogues. Endocrinology. 2001;142(10):4250-4256. (GHRP-6 orexigenic effect)
- Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews. 1998;19(6):717-797. (GH axis regulation)
- Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. (Ghrelin/GHS-R1a discovery)
- Fairhall KM, et al. Growth hormone secretagogue receptor hyper-sensitivity in obesity. Diabetes. 2015;64(4):1160-1170. (GHS-R1a somatostatin interaction)
- Veldhuis JD, et al. Pulsatile growth hormone secretion: mechanisms and physiological relevance. Recent Progress in Hormone Research. 2001;56:293-317. (Pulsatile GH physiology)
- Martinez AG, et al. CJC-1295 and Ipamorelin: a review of growth hormone-releasing hormone analogs and growth hormone secretagogues. Journal of Medicinal Chemistry. 2022;65(12):8033-8051. (Mod GRF stability and pharmacokinetics)
- Guillen M, et al. Growth hormone-releasing peptides: a review of pharmacology and clinical applications. Current Pharmaceutical Design. 2019;25(12):1395-1406. (GHRP-6 comprehensive review)
| SKU | BLEND-MODGHRP6-10 |
| Category | Peptide Blends |
| Form | Lyophilized powder (co-lyophilized blend) |
| Components | Mod GRF 1-29 5mg + GHRP-6 5mg |
| Total Content | 10mg per vial |
| Blend Ratio | 1:1 (Mod GRF 1-29 : GHRP-6 by weight) |
| Mod GRF Type | Short-acting GHRH analog (D-Ala2, Ala8), no DAC |
| Mod GRF Half-life | ~30 minutes |
| GHRP-6 Type | Original synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) |
| GHRP-6 Half-life | ~15-30 minutes |
| Purity | ≥99% (HPLC) |
| Storage | Room temperature, dry place; refrigerate after reconstitution |
| Reconstitution | Add bacteriostatic water; gentle swirl to dissolve |
Why is GHRP-6 known as the "original" GHRP?
GHRP-6 was the first synthetic growth hormone-releasing peptide discovered by Dr. Cyril Bowers in the 1980s. It is the reference compound against which all subsequent GHRPs (GHRP-2, Ipamorelin, Hexarelin, etc.) are compared. Its sequence (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) established the structural motif for the entire GHRP family.
Does GHRP-6 increase appetite?
Yes, GHRP-6 has a well-documented orexigenic (appetite-stimulating) effect, particularly at higher doses. This is because GHS-R1a receptors are expressed not only in the pituitary but also in hypothalamic appetite-regulating centers. For research focused on GH release without significant appetite effects, Ipamorelin or GHRP-2 may be preferred.
What makes Mod GRF (1-29) different from native GHRH?
Native GHRH (1-29) has a very short half-life (less than 10 minutes) due to rapid enzymatic degradation by DPP-IV (cleaves at Ala2) and endopeptidases. Mod GRF (1-29) incorporates D-Ala2 (resistant to DPP-IV), Ala8 (resistant to endopeptidases), and Gln29 substitutions, extending its half-life to approximately 30 minutes while maintaining the short-acting, pulsatile profile.
How does the synergy between GHRH and GHRP-6 work at the molecular level?
GHRH activates the GHRHR, a Gs-coupled receptor that increases cAMP and activates PKA. GHRP-6 activates GHS-R1a, a Gq-coupled receptor that activates PLC, producing IP3 (which releases intracellular calcium) and DAG (which activates PKC). These two pathways converge on the somatotroph to increase intracellular calcium and GH exocytosis. Additionally, GHRP-6 suppresses hypothalamic somatostatin, removing the inhibitory "brake" on GH release.
Is this blend suitable for long-term research protocols?
The short-acting nature of both components means they are typically administered via subcutaneous injection multiple times per day in research protocols. The co-lyophilized formulation simplifies dosing. For long-term studies, researchers should monitor GH, IGF-1, glucose, and other metabolic markers, as chronic GH secretagogue administration can lead to desensitization and metabolic changes.
Certificate of Analysis
Product: Mod GRF (1-29) & GHRP-6 Blend (10mg)
Batch / COA Code: BLEND-MODGHRP6-10
| Test Item | Specification | Result |
|---|---|---|
| Appearance | White lyophilized powder | Complies |
| Purity (HPLC) | ≥99.0% | 99.50-99.85% |
| Identity (Mass Spec) | Confirmed molecular weight | Confirmed |
| Peptide Content | ≥80% | ≥85% |
| Water Content (Karl Fischer) | ≤5.0% | ≤3.2% |
| Endotoxin (LAL) | ≤10 EU/mg | ≤2.5 EU/mg |
| Sterility | Sterile filtration | Pass |
| Heavy Metals | ≤10 ppm | ≤2 ppm |
This COA is for reference only. Each batch is individually tested. Contact us for the specific batch certificate.